[go: up one dir, main page]

DK1176956T3 - Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer - Google Patents

Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer

Info

Publication number
DK1176956T3
DK1176956T3 DK00937527T DK00937527T DK1176956T3 DK 1176956 T3 DK1176956 T3 DK 1176956T3 DK 00937527 T DK00937527 T DK 00937527T DK 00937527 T DK00937527 T DK 00937527T DK 1176956 T3 DK1176956 T3 DK 1176956T3
Authority
DK
Denmark
Prior art keywords
binding
receptors
inhibit
integrins
carboxylic acid
Prior art date
Application number
DK00937527T
Other languages
English (en)
Inventor
Ronald J Biediger
Qi Chen
George W Holland
Jamal M Kassir
Wen Li
Robert V Market
Ian L Scott
Chengde Wu
Original Assignee
Encysive Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encysive Pharmaceuticals Inc filed Critical Encysive Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1176956T3 publication Critical patent/DK1176956T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00937527T 1999-05-07 2000-05-05 Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer DK1176956T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13297199P 1999-05-07 1999-05-07
PCT/US2000/012303 WO2000067746A1 (en) 1999-05-07 2000-05-05 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors

Publications (1)

Publication Number Publication Date
DK1176956T3 true DK1176956T3 (da) 2008-05-26

Family

ID=22456441

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00937527T DK1176956T3 (da) 1999-05-07 2000-05-05 Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer

Country Status (23)

Country Link
EP (1) EP1176956B1 (da)
JP (1) JP5132855B2 (da)
AT (1) ATE383153T1 (da)
AU (1) AU5267900A (da)
CA (1) CA2373360C (da)
CY (1) CY1107438T1 (da)
CZ (1) CZ303312B6 (da)
DE (1) DE60037726T2 (da)
DK (1) DK1176956T3 (da)
ES (1) ES2296625T3 (da)
IL (2) IL146311A0 (da)
IN (1) IN2001KN01110A (da)
MX (1) MXPA01011340A (da)
NO (1) NO324421B1 (da)
NZ (1) NZ515248A (da)
PL (1) PL205322B1 (da)
RO (1) RO122246B1 (da)
RU (1) RU2263109C2 (da)
SI (1) SI20744B (da)
SK (1) SK286696B6 (da)
TR (2) TR200201920T2 (da)
WO (1) WO2000067746A1 (da)
ZA (1) ZA200108774B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972296B2 (en) * 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
SI21096B (sl) * 2001-10-09 2012-05-31 Encysive Pharmaceuticals Inc Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje
SI1490064T1 (sl) * 2002-02-14 2010-01-29 Pharmacia Corp Substituirani piridinoni kot modulatorji p38 MAP kinaze
BR0312232A (pt) 2002-06-28 2005-05-10 Vertex Pharma Inibidores de caspases e seus usos
CN1703395A (zh) 2002-08-09 2005-11-30 特兰斯泰克制药公司 芳基和杂芳基化合物以及调节凝血的方法
WO2004044046A2 (en) * 2002-11-08 2004-05-27 Encysive Pharmaceuticals Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
WO2004058718A1 (en) 2002-12-20 2004-07-15 Vertex Pharmaceuticals Incorporated 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
WO2005014532A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
EP1917244A2 (de) 2005-08-24 2008-05-07 Abbott GmbH & Co. KG Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
CA2680366C (en) * 2007-03-09 2016-06-21 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
CA2677049A1 (en) 2007-08-01 2009-02-05 Sionex Corporation Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
SG175355A1 (en) * 2009-04-27 2011-12-29 Elan Pharm Inc Pyridinone antagonists of alpha-4 integrins
WO2012033548A2 (en) * 2010-09-07 2012-03-15 E. I. Du Pont De Nemours And Company Herbicidal bis-nitrogen-containing oxo and sulfono heterocycles
US8952024B2 (en) 2009-09-09 2015-02-10 E I Du Pont De Nemours And Company Herbicidal pyrimidone derivatives
AU2013216006B2 (en) * 2012-01-31 2017-06-08 Daiichi Sankyo Company, Limited Pyridone derivatives
US10227323B2 (en) 2013-09-20 2019-03-12 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
EP3116910A1 (en) 2014-03-13 2017-01-18 Prothena Biosciences Limited Combination treatment for multiple sclerosis
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10246451B2 (en) * 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
CN111093717B (zh) * 2017-04-28 2023-01-31 德克萨斯州儿童医院 靶向性纳米颗粒
CA3090270A1 (en) * 2018-02-02 2019-08-08 Genentech, Inc. Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614189A1 (de) * 1976-04-02 1977-10-20 Hoechst Ag Therapeutisch wirksame ureido- und semicarbazido-derivate des tiazols und verfahren zu ihrer herstellung
US5220017A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
ATE195117T1 (de) * 1993-03-31 2000-08-15 Searle & Co 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
AU672699B2 (en) * 1993-06-30 1996-10-10 Sankyo Company Limited Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
JPH07304755A (ja) * 1994-05-12 1995-11-21 Yamanouchi Pharmaceut Co Ltd 縮合ジアゼピン誘導体
US5610296A (en) * 1994-12-05 1997-03-11 G. D. Searle & Co. Process for the preparation of amidino phenyl pyrrolidine beta-alanine urea analogs
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1997043650A1 (en) * 1996-05-15 1997-11-20 G.D. Searle & Co. Method and reagent for monitoring blood levels of antiplatelet compounds
AU723315B2 (en) * 1996-09-18 2000-08-24 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6025358A (en) * 1998-06-11 2000-02-15 G. D. Searle & Co. Double prodrugs of potent GP IIb/IIIa antagonists
WO2000017197A1 (en) * 1998-09-21 2000-03-30 Biochem Pharma Inc. Quinolizinones as integrin inhibitors

Also Published As

Publication number Publication date
JP2002544161A (ja) 2002-12-24
CY1107438T1 (el) 2012-12-19
RU2263109C2 (ru) 2005-10-27
IN2001KN01110A (da) 2015-06-05
AU5267900A (en) 2000-11-21
SI20744B (sl) 2009-08-31
WO2000067746A8 (en) 2002-02-28
PL351396A1 (en) 2003-04-07
CA2373360A1 (en) 2000-11-16
WO2000067746A1 (en) 2000-11-16
HK1045805A1 (en) 2002-12-13
SI20744A (sl) 2002-06-30
ZA200108774B (en) 2003-01-24
NO20015418D0 (no) 2001-11-06
JP5132855B2 (ja) 2013-01-30
ES2296625T3 (es) 2008-05-01
IL146311A (en) 2011-10-31
EP1176956A4 (en) 2002-08-28
IL146311A0 (en) 2002-07-25
ATE383153T1 (de) 2008-01-15
WO2000067746A9 (en) 2002-08-29
CZ20013963A3 (cs) 2002-04-17
CA2373360C (en) 2011-09-06
EP1176956B1 (en) 2008-01-09
NZ515248A (en) 2004-01-30
TR200103178T2 (tr) 2002-05-21
DE60037726D1 (de) 2008-02-21
SK16082001A3 (sk) 2002-04-04
EP1176956A1 (en) 2002-02-06
CZ303312B6 (cs) 2012-07-25
DE60037726T2 (de) 2009-03-05
NO20015418L (no) 2001-12-21
TR200201920T2 (tr) 2002-09-23
PL205322B1 (pl) 2010-04-30
RO122246B1 (ro) 2009-03-30
NO324421B1 (no) 2007-10-08
SK286696B6 (sk) 2009-03-05
MXPA01011340A (es) 2003-08-01

Similar Documents

Publication Publication Date Title
DK1176956T3 (da) Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer
DK1203766T3 (da) Carboxylisyrederivater, der hæmmer bindingen af integriner til deres receptorer
NO20005162D0 (no) Forbindelser som inhiberer bindingen av integriner til deres reseptorer
NO20015419D0 (no) Propionsyrederivater som hemmer binding av integriner til deres reseptorer
ATE420876T1 (de) Propansäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
CA2361285A1 (en) Propanoic acid derivatives that inhibit the binding of integrins to their receptors